Title: Overall Survival and Toxicity of Y90 Radioembolization for Hepatocellular Carcinoma
Patients in Barcelona Clinic Liver Cancer Stage C (BCLC-C)
Version: 2 Date: 13 Apr 2022
Reviewer's report:
Dear Authors, the work is about an observational study  on TARE in BCLC-C  HCC patients.
The results bring to the light, for another time, the question if in this setting it would be better
a chemotherapy  or a TARE. The results are encouranging but too limited to give some clinical
strong indications. We would need prospective and comparative trials between the more recent
chemotherapies and TARE, in terms of toxicity and OS. In the meanwhile, all studies results
could help us to identify the ideal patients to give one or another HCC therapy, but too often the
choice is oriented by local experience and local availability of therapies.
Moreover, it is not so clear from the paper,  how many treatments (i.e. procedures) for single
patient have been performed (the data could be insert in the table), and the median time in
months, to the onset of liver function worsening, in the cases  when it occurred (i.e. it could be
dependent by TARE of physiological progressive liver failure due to cirrhosis?).
Title: Overall Survival and Toxicity of Y90 Radioembolization for Hepatocellular Carcinoma
Patients in Barcelona Clinic Liver Cancer Stage C (BCLC-C)
Version: 2 Date: 13 Apr 2022
Reviewer's report:
Dear Authors, the work is about an observational study  on TARE in BCLC-C  HCC patients.
The results bring to the light, for another time, the question if in this setting it would be better
a chemotherapy  or a TARE. The results are encouranging but too limited to give some clinical
strong indications. We would need prospective and comparative trials between the more recent
chemotherapies and TARE, in terms of toxicity and OS. In the meanwhile, all studies results
could help us to identify the ideal patients to give one or another HCC therapy, but too often the
choice is oriented by local experience and local availability of therapies.
Moreover, it is not so clear from the paper,  how many treatments (i.e. procedures) for single
patient have been performed (the data could be insert in the table), and the median time in
months, to the onset of liver function worsening, in the cases  when it occurred (i.e. it could be
dependent by TARE of physiological progressive liver failure due to cirrhosis?).
Please review this paper.
user
Title: Overall Survival and Toxicity of Y90 Radioembolization for Hepatocellular Carcinoma
Patients in Barcelona Clinic Liver Cancer Stage C (BCLC-C)
Version: 2 Date: 13 Apr 2022
Reviewer's report:
Dear Authors, the work is about an observational study  on TARE in BCLC-C  HCC patients.
The results bring to the light, for another time, the question if in this setting it would be better
a chemotherapy  or a TARE. The results are encouranging but too limited to give some clinical
strong indications. We would need prospective and comparative trials between the more recent
chemotherapies and TARE, in terms of toxicity and OS. In the meanwhile, all studies results
could help us to identify the ideal patients to give one or another HCC therapy, but too often the
choice is oriented by local experience and local availability of therapies.
Moreover, it is not so clear from the paper,  how many treatments (i.e. procedures) for single
patient have been performed (the data could be insert in the table), and the median time in
months, to the onset of liver function worsening, in the cases  when it occurred (i.e. it could be
dependent by TARE of physiological progressive liver failure due to cirrhosis?).
assistant